The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin

Br J Pharmacol. 2004 Nov;143(5):520-3. doi: 10.1038/sj.bjp.0705968. Epub 2004 Sep 20.

Abstract

The paraventricular nucleus (PVN) of the hypothalamus plays a key role in the control of appetite and energy balance. Both ghrelin and cannabinoid receptor agonists increase food intake when administered into this nucleus: this study investigated possible interactions between the two systems in relation to eating. The orexigenic effect of ghrelin (100 pmol) when infused in to the PVN was reversed by a small, systemic dose of the CB(1) cannabinoid receptor antagonist SR141716 (1 mg kg(-1)). This is the first demonstration of a functional relationship between brain ghrelin and endocannabinoid systems, and, although it needs to be further investigated, the effect of ghrelin on food intake when injected into the PVN seems to be mediated by stimulation of cannabinoid release.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Appetite Stimulants / administration & dosage
  • Appetite Stimulants / antagonists & inhibitors*
  • Dronabinol / antagonists & inhibitors
  • Dronabinol / pharmacology
  • Eating / drug effects
  • Ghrelin
  • Male
  • Microinjections
  • Paraventricular Hypothalamic Nucleus / physiology*
  • Peptide Hormones / administration & dosage
  • Peptide Hormones / antagonists & inhibitors*
  • Peptide Hormones / pharmacology
  • Piperidines / pharmacology*
  • Pyrazoles / pharmacology*
  • Rats
  • Receptor, Cannabinoid, CB1 / drug effects*
  • Rimonabant

Substances

  • Appetite Stimulants
  • Ghrelin
  • Peptide Hormones
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Dronabinol
  • Rimonabant